| A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T (NCT05468190) | Chongqing Precision Biotech Co., Ltd | 2022-07-17 |
| Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC (NCT05485896) | Tianjin Medical University Second Hospital | 2022-07-01 |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (NCT04981509) | National Cancer Institute (NCI) | 2022-06-10 |
| REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (NCT04913025) | University College, London | 2022-05-26 |
| Biomarkers of Response to Systemic Treatments in FH-deficient RCC (NCT05243173) | RenJi Hospital | 2022-05-25 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05311618) | NGM Biopharmaceuticals, Inc | 2022-05-11 |
| Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer (NCT05285579) | Assistance Publique - Hôpitaux de Paris | 2022-05-05 |
| A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland. (NCT05363072) | Pfizer | 2022-05-02 |
| A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 (NCT05354102) | Biomica Ltd. | 2022-05-01 |
| Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NCT05148546) | The Netherlands Cancer Institute | 2022-04-28 |
| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors (NCT05229601) | HiFiBiO Therapeutics | 2022-04-20 |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (NCT05293496) | MacroGenics | 2022-04-19 |
| Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors (NCT05215574) | NGM Biopharmaceuticals, Inc | 2022-03-31 |
| PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology (NCT05592665) | UNC Lineberger Comprehensive Cancer Center | 2022-03-18 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT05621837) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2022-03-10 |
| A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (NCT05238883) | HiFiBiO Therapeutics | 2022-03-10 |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (NCT05078047) | UNICANCER | 2022-03-08 |
| Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer (NCT07436416) | Institute of Oncology Ljubljana | 2022-03-01 |
| NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts (NCT04960059) | The Christie NHS Foundation Trust | 2022-02-11 |
| Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma (NCT04955743) | Yale University | 2022-02-09 |
| Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT (NCT05023265) | Sunnybrook Health Sciences Centre | 2022-02-08 |
| Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population (NCT05863052) | University of Oklahoma | 2022-01-31 |
| Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer (NCT05420519) | Chongqing Precision Biotech Co., Ltd | 2021-12-31 |
| A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors (NCT05420545) | Chongqing Precision Biotech Co., Ltd | 2021-12-31 |
| Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (NCT05013099) | ImaginAb, Inc. | 2021-12-09 |
| Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma (NCT05124431) | Fudan University | 2021-12-01 |
| Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617 (NCT05170555) | Peking Union Medical College Hospital | 2021-12-01 |
| The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors (NCT05037825) | VastBiome | 2021-11-22 |
| Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (NCT05024214) | 3D Medicines (Sichuan) Co., Ltd. | 2021-11-15 |
| Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1) (NCT07406646) | Institute of Oncology Ljubljana | 2021-11-02 |
| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT05119335) | NiKang Therapeutics, Inc. | 2021-10-26 |
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) (NCT05030506) | Merck Sharp & Dohme LLC | 2021-10-13 |
| Circulating Tumor Cell Reducing No-touch Nephrectomy (NCT05070637) | Hospital de Santa Maria, Portugal | 2021-09-27 |
| Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) (NCT05012865) | Pfizer | 2021-09-14 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (NCT05059444) | Guardant Health, Inc. | 2021-09-07 |
| Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma (NCT04995016) | Tianjin Medical University Second Hospital | 2021-08-20 |
| [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma (NCT04989959) | Orhan Kemal Oz | 2021-08-18 |
| Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (NCT04787042) | Simcha IL-18, Inc. | 2021-08-06 |
| A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer (NCT04958473) | Tianjin Medical University Second Hospital | 2021-08-01 |
| A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients (NCT05375136) | Eisai Korea Inc. | 2021-06-25 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) (NCT04834778) | HiberCell, Inc. | 2021-06-08 |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (NCT04903873) | Eutilex | 2021-05-31 |
| Yorkshire Kidney Screening Trial (NCT05005195) | University of Leeds | 2021-05-10 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy (NCT04892849) | University of Erlangen-Nürnberg Medical School | 2021-04-30 |
| Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma (NCT04804813) | Takeda | 2021-03-29 |
| Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma (NCT04831138) | University of Texas Southwestern Medical Center | 2021-03-24 |
| Research on the Effectiveness and Safety of Remote Control of Domestic Surgical Robot System for Urinary Surgery (NCT04804163) | The Affiliated Hospital of Qingdao University | 2021-02-27 |
| Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma (NCT04669860) | University of Miami | 2021-02-24 |
| Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (NCT04704219) | Merck Sharp & Dohme LLC | 2021-02-23 |
| Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma (NCT04758507) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-02-18 |
| Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer (NCT04883827) | Vanderbilt-Ingram Cancer Center | 2021-01-06 |
| VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma (NCT04666220) | Humanitas Clinical and Research Center | 2021-01-02 |
| A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (NCT04262375) | University Health Network, Toronto | 2021-01-01 |
| A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors (NCT04707248) | Daiichi Sankyo | 2020-12-22 |
| Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma (NCT04535687) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-12-17 |
| Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors (NCT04628780) | Pfizer | 2020-12-16 |
| Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity (NCT04631731) | Western Sydney Local Health District | 2020-12-15 |
| Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) (NCT04508725) | Stanford University | 2020-12-05 |
| Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief (NCT04177056) | Hamilton Health Sciences Corporation | 2020-12-04 |
| Residual Normal Renal Parenchymal and Tumor Volume in Tumor Surgeries (NCT04244136) | Assiut University | 2020-12-01 |
| Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England (NCT04637204) | Ipsen | 2020-11-24 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy (NCT04596033) | Genocea Biosciences, Inc. | 2020-11-11 |
| Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC (NCT04413123) | Bradley A. McGregor, MD | 2020-11-05 |
| A Study of PY314 in Subjects With Advanced Solid Tumors (NCT04691375) | Ikena Oncology | 2020-10-29 |
| PET/MR Characterization of Renal Cell Carcinomas (NCT04271254) | UNC Lineberger Comprehensive Cancer Center | 2020-10-01 |
| The Incidence of Pulmonary Embolism During Nephrectomy (NCT04402749) | Mahidol University | 2020-10-01 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| Anesthesia and Cancer Study: Renal Cell Carcinoma (NCT04503148) | Seoul National University Hospital | 2020-09-22 |
| Axitinib Therapy Management Study (NCT04555603) | Pfizer | 2020-09-15 |
| A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) (NCT04495257) | Yale University | 2020-09-14 |
| A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (NCT04540705) | Bristol-Myers Squibb | 2020-09-11 |
| A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma (NCT04088500) | Bristol-Myers Squibb | 2020-09-03 |
| PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma (NCT03598816) | Washington University School of Medicine | 2020-08-31 |
| Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System (NCT04570176) | The Affiliated Hospital of Qingdao University | 2020-08-27 |
| Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (NCT04495894) | Emory University | 2020-08-24 |
| MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial (NCT04580836) | M.D. Anderson Cancer Center | 2020-08-19 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies (NCT04440943) | Celldex Therapeutics | 2020-08-04 |
| Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney Surgery (NCT04601129) | University Hospital, Lille | 2020-08-01 |
| Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) (NCT04267120) | Washington University School of Medicine | 2020-07-29 |
| Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma (NCT04341740) | University of Oklahoma | 2020-07-22 |
| Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Renal Cell Carcinoma (NCT04424472) | University of Kansas Medical Center | 2020-07-17 |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) (NCT04438083) | CRISPR Therapeutics AG | 2020-06-16 |
| Robotic-assisted vs. Open Partial Nephrectomy (NCT04534998) | Universitätsmedizin Mannheim | 2020-06-15 |
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab (NCT04074967) | Dan Zandberg | 2020-06-11 |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (NCT04301011) | Turnstone Biologics, Corp. | 2020-06-02 |
| Sintilimab in FH-deficient Renal Cell Carcinoma (NCT04146831) | West China Hospital | 2020-06-01 |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer (NCT04337970) | Memorial Sloan Kettering Cancer Center | 2020-04-06 |
| Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma (NCT04260360) | NanOlogy, LLC | 2020-04-01 |
| A Multicenter Cancer Biospecimen Collection Study (NCT04510129) | Cofactor Genomics, Inc. | 2020-02-05 |
| Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation (NCT04163289) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2020-01-23 |
| Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease (NCT03709771) | Vanderbilt University Medical Center | 2020-01-09 |
| Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma. (NCT04213664) | Corporacion Parc Tauli | 2019-12-31 |
| Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (NCT03961698) | Infinity Pharmaceuticals, Inc. | 2019-12-17 |
| Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology (NCT03948724) | Institut Cancerologie de l'Ouest | 2019-12-11 |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (NCT04198766) | Inhibrx Biosciences, Inc | 2019-12-10 |
| 3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement (NCT03738488) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2019-12-01 |
| Spanish Real-World Evidence Cabozantinib (NCT04510688) | Spanish Oncology Genito-Urinary Group | 2019-10-23 |
| Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. (NCT04134182) | Kidney Cancer Research Bureau | 2019-10-16 |